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Targeting cannabidiol to specific areas 
of the brain: an ultrasound-based 
strategy
Brain diseases, ranging from central nervous system (CNS) dis-
orders to brain cancers, are some of the most prevalent pathol-
ogies in the world. Despite the high incidence, many of these 
diseases lack successful treatments because of inadequate drug 
development in comparison to other therapeutic areas. In par-
ticular, even if many drugs have shown the potential to tackle 
some neurological disorders including Alzheimer’s and Parkin-
son’s diseases and many other associated CNS pathologies, their 
delivery in specific brain areas and in adequate concentrations 
represent the real obstacle to the treatment of these pathologies. 
The reason for this is twofold. First, the presence of the blood-
brain barrier (BBB) ensures that the brain is separated by the 
systemic circulation. Indeed, the BBB is a well-known complex 
anatomical structural barrier that plays a pivotal role in protect-
ing the parenchyma of the CNS from potential toxicants and 
dangerous elements that could be present in the blood circula-
tion (Branca et al., 2019b). For this reason, the BBB is the main 
obstacle that prevents most systematically administered drugs 
from entering the CNS. In these instances, the link of lipid 
groups to the polar ends of the therapeutic molecules were used 
to enhance drug delivery across the BBB. Similarly, ligands, in-
volved in the specific interactions with endothelial transporters, 
were often incorporated into the therapeutic agents for the ini-
tiation of receptor-mediated transcytosis at BBB endothelium. 
Despite these strategies, many studies have reported that less 
than 1% of total injected dose reaches the brain by intravenous 
administration because the BBB hinders about 95% of drug de-
livery (Dong, 2018).
Secondly, the inabilities to deliver relevant doses of the ther-
apeutic and to maintain a high targeting efficiency to diseased 
regions, make difficult to achieve effective therapies in the CNS. 
Linking lipids to therapeutics also did not help to sort out the 
problem of targeting a specific area: this process allows drugs 
to increase their hydrophobicity facilitating their distribution 
throughout the brain rather than in a specific region. To over-
come the BBB hindrance, the use of the lipophilic molecule of 
cannabidiol (CBD) has been suggested. CBD has been demon-
strated to bind to various receptors located on the brain endo-
thelium environment, and some authors have clearly demon-
strated that the decoration of lipid nanocapsule with CBD can 
overcome the BBB impermeability to deliver therapies for CNS 
diseases (Aparicio-Blanco et al., 2019).
The CBD molecule is the non-psychoactive extract com-
ponent of the officinalis plant Cannabis sativa (about 40% of 
extract), that has been used for many years in the past both for 
medicinal and recreational purposes. In addition to its tolera-
bility in humans (up to 1500 mg/d are well tolerated), CBD also 
lacks in affecting mental processes, e.g. cognition or affect, and 
exhibits a broad spectrum of potential therapeutic properties in 
neurological disorders such as psychosis, epilepsy, anxiety and 
sleep, and in neurodegenerative disease such as Alzheimer’s, 
Parkinson’s and Huntington’s diseases (Izzo et al., 2009). 
The mechanisms responsible for the wide range of CBD po-
tential neuroprotective effects are not completely understood. 
In the last decade, many data demonstrated that multiple phar-
macological targets are involved. Although CBD has a very 
low affinity for cannabinoid receptors, some of its effects seem 
to involve the cannabinoid receptor types 1 and 2, the most 
abundant neuromodulatory receptors in the brain and in the 
immune system, respectively (Long et al., 2005). CBD activates 
the transient receptor potential vanilloid channel-1, serotonin 
receptor 5-HT1A, or modulate G protein-coupled receptors. 
CBD may also interact with transcription factors, such as the 
G-protein coupled receptor 55 and the nuclear receptors of the 
peroxisome proliferator-activated receptor family (Calapai et 
al., 2020). The beneficial effects of CBD on brain disorders have 
also been associated with its capacity of modulating pro-inflam-
matory cytokines and brain-derived neurotrophic factor ex-
pression (Bih et al., 2015). Recently, in vitro and in vivo studies 
showed that CBD prevents the oxidative stress-dependent cell 
death probably acting as an endoplasmic reticulum stress atten-
uator and preserving the cellular redox potential (Branca et al., 
2019a).
All these effects clearly indicate that CBD represents a new 
opportunity for the treatment of several disorders and make 
CBD activity of interest for a variety of medical purposes and 
therapeutic approaches. On this regard, we recently published 
in vitro data demonstrating that CBD is able to ameliorate the 
cadmium-induced neuronal toxicity (Branca et al., 2019a), thus 
making CBD a reasonable candidate to protect neurons from 
heavy metal-induced neuronal toxicity.
However, although many molecules such as ion channels, re-
ceptors, transporters, and enzymes have been suggested as likely 
CBD target, studies demonstrating which of these molecules 
underlie each specific therapeutic effect are scarce. Moreover, 
it would be of paramount importance to identify novel mecha-
nistic pathways through which CBD exerts its properties; these 
findings will have important implications for understanding the 
mechanism of the CBD therapeutic effects.
Another important aspect to be considered is the different 
route of CBD administration. 
Many pharmacokinetic studies have focused on the different 
path by which CBD can be taken into the body (i.e. subcuta-
neous, oral, inhalational, intravenous and intraperitoneal) and 
concluded that the highest CBD levels in the brain are reached 
after oral administration (Calapai et al., 2020). Although the 
lipophilic nature of CBD enables it to traverse the BBB, oral 
administration most often lack efficiency, does not allow reach-
ing therapeutic dose in a specific brain region and is linked to 
drug-mediated toxicity. This scenario makes it necessary to de-
vise a non-invasive, transient, and regionally selective brain CBD 
delivery method in order to restrict delivery into target areas, 
minimizing the toxicity-dependent systemic distribution of the 
therapeutic. 
To this end, ultrasound (US)-mediated delivery, also known 
as sonography, allows spatially confined delivery of drugs into 
target areas. This approach has emerged as a non-invasive, and 
safe diagnostic medical imaging technique that uses sound 
waves to produce dynamic visual images of organs, tissues, 
tumors, cysts or blood flow (e.g. splenic blood flow by echo-co-
lour-doppler assistance) inside the body (Ward et al., 2014). In 
addition, a parallel study has shown the non-invasiveness of 
this approach that makes US-induced BBB opening a novel and 
attractive means to perform localized CNS therapeutic agent 
delivery (McMahon et al., 2019).
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Moreover, such a technique, can be used alone or in com-
bination with different nanocarriers (polymer nanoparticles, 
liposomes, micelles, and microbubbles), to deliver different 
molecules, drugs or genes to a target site (such as various tissues 
and organs, including tumor tissues, kidney, cardiac, skeletal 
muscle, and vascular smooth muscle), with minimal loss of the 
initial dose (Beccaria et al.,  2020).
Interestingly, many researchers are combining these appli-
cations for treating a variety of diseases and this approach was 
validated both by in vitro and in vivo experiments. On this 
regard, one of the new and intriguing emerging aspects about 
the US application for specific target, especially for brain drug 
delivery, is their combination with microbubbles. Microbubbles 
are spheroidal bubbles, typically ranging from 0.5 µm to 10 µm 
in diameter, with a gas core used to deliver drugs and able to 
vary their size upon interaction with US. Thus, the application 
of US to a specific area could provide highly efficient to target 
drug-loaded microbubbles to that area. This safe and non-in-
vasive strategy has been used successfully to deliver treatments 
across the BBB to a specific area of the brain (Yang et al., 2019). 
Such an application is of great interest given the properties of 
the BBB. This unique and dynamic structure at the interface 
between the cerebral circulation and the brain tissue, that is es-
sential for maintaining the microenvironment within the brain, 
displays a highly selectivity nature that in turn makes difficult 
to reach specific brain areas with the appropriate pharmaco-
logical intervention. Also, the targeted delivery of therapeutics 
to specific brain area have the potential to prevent damages to 
neighboring areas, an important side effect of many therapies. 
Therefore, the US application in a specific cerebral area, related 
to a particular CNS pathology, allows the breaking of the mi-
crobubbles containing CBD in the brain microvessels. This, in 
turn, induces the presence of a greater free fraction of CBD in 
the area irradiated by US that will facilitate its diffusion through 
the BBB to target the region of interest (Figure 1).
However, at this time not much is known on the US-mediat-
ed gene and protein expression. Does US cause a stress response 
(similar to heat shock) that may enhance or interfere with the 
action of drugs? Is this response similar for all cells and does it 
differ for various ultrasonic frequencies and intensities? These 
and other questions need to be addressed.
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Figure 1 Representative image of microbubbles CBD-loaded and 
delivered in specific brain area by US application.
US waves are directed to the brain region where CBD needs to be 
carried; when the CBD-loaded circulating microbubbles are hit by the 
US waves, they break and release the CBD exactly in the brain region 
where the waves have already partially opened the BBB. BBB: Blood-
brain barrier; CBD: cannabidiol; US: ultrasound.
